GSK acquires part of 23andme for $300m to stimulate drug discovery

GlaxoSmithKline has announced today it has acquired part of the California-based biotech engineering company 23andme from investors Sequoia Capital and Google Ventures, plus some minor investors. As part of the agreement, GSK will pay $300m to access 23andme’s rich database, including information about 4 million people. The database may help develop ad-hoc therapies for challenging diseases, such as Parkinson.

(Source: GSK)